|
USA-AZ-PIMA ไดเรกทอรีที่ บริษัท
|
ข่าว บริษัท :
- Our Leaders | AbbVie
Our board members work closely with AbbVie leaders to maintain our focus of putting patients first Robert A Michael Chairman of the Board and Chief Executive Officer AbbVie Inc North Chicago, Illinois Robert J Alpern, M D Ensign Professor of Medicine and Physiology, Professor of Internal Medicine and Cellular and Molecular Physiology, and
- AbbVie Announces Appointment of Robert A. Michael as Chief Executive . . .
NORTH CHICAGO, Ill , Feb 20, 2024 PRNewswire -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously selected Robert A Michael, AbbVie's current president and chief operating officer, to succeed Richard A Gonzalez as the company's chief executive officer (CEO)
- Robert A. Michael | AbbVie
Rob Michael is the Chairman of the Board and Chief Executive Officer of AbbVie, a global biopharmaceutical company that employs approximately 55,000 people worldwide and has provided innovative medicines and products to more than 60 million people in over 175 countries
- Robert A. Michael Assumes Role as AbbVie Chief Executive Officer
NORTH CHICAGO, Ill , July 1, 2024 PRNewswire -- AbbVie (NYSE: ABBV) today announced that Robert A Michael has assumed the role of chief executive officer (CEO) and has joined AbbVie's Board of Directors, effective today
- AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of . . .
NORTH CHICAGO, Ill , Feb 14, 2025 PRNewswire -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A Michael to assume the additional position of chairman, effective July 1, 2025
- AbbVie Reports First-Quarter 2025 Financial Results
AbbVie announced that its board of directors unanimously elected chief executive officer (CEO) Robert A Michael to assume the additional position of chairman of the board of directors, effective July 1, 2025
- AbbVie Reports Second-Quarter 2025 Financial Results | AbbVie
We also made meaningful pipeline progress with several regulatory approvals, encouraging clinical data and strategic investments in promising external innovation," said Robert A Michael, chairman and chief executive officer, AbbVie
- AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog . . .
"At AbbVie, we are focused on transforming the future of patient care in areas where significant unmet need persists," said Robert A Michael, chief executive officer, AbbVie
- Pharmaceutical Research Development | AbbVie
AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives
- AbbVie Reports First-Quarter 2025 Financial Results | AbbVie
AbbVie announced that its board of directors unanimously elected chief executive officer (CEO) Robert A Michael to assume the additional position of chairman of the board of directors, effective July 1, 2025
|
|